On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended adding a new indication for isatuximab, a monoclonal antibody treatment marketed by Sanofi as Sarclisa ®. The CHMP is the European Medicines Agency’s committee playing a significant role in the assessment and authorisation of human medicines. The new indication for isatuximab…
Last week Myeloma Patients Europe (MPE) provided feedback, as part of a public consultation, on the new European Medicines Agency (EMA) policy on the handling of competing interests of scientific committees’ members and experts. The new policy increases restrictions for the participation of experts, including patient experts, in the EMA procedures assessing specific medical products.…
Yesterday 28 October, MPE provided feedback, as part of a public consultation open to all categories of stakeholders, on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level. This is the fourth implementing act (out of six planned to be adopted this year) paving the road for the…
The Myeloma Patients Europe (MPE) European Young Myeloma Patient Group (EYMPG) held the webinar “Importance of good nutrition and healthy diet for young myeloma patients”. The webinar was given by Inês Almada Correia, Nutritionist specialising in Oncology and Autoimmunity, from Portugal. Watch the recording below: Learn more about the EYMPG here.
September is an important month for Myeloma Patients Europe (MPE) and our members. Each year, as part of Blood Cancer Awareness Month, we hold European Myeloma Day on 27 September. This year focused on highlighting the role of clinical trials in advancing myeloma treatments and improving patients’ quality of life. Throughout September, our members organised different activities to raise awareness of myeloma…
Brussels, 27 September 2024 – Today is European Myeloma Day, a date dedicated to raising awareness of key issues affecting myeloma patients across Europe. This year, Myeloma Patients Europe (MPE) is highlighting the role of clinical trials in advancing myeloma treatments and improving patients Quality of Life (QoL). Despite of the importance of clinical trials…
On 19 September the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for daratumumab (Darzalex®, commercialised by Janssen). The new indication is a combination of daratumumab, bortezomib, lenalidomide and dexamethasone and it brings a significant benefit with respect to progression-free survival compared to…
